EVENT March 11, 2017

Preliminary Data with Bertilimumab in an Open Label Phase 2a Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid, presented at the American Academy of Dermatology 2017 Annual Meeting in Orlando, FL.

Preliminary Data with Bertilimumab in an Open Label Phase 2a Study in Bullous Pemphigoid were presented last Saturday at the American Academy of Dermatology 2017 Annual Meeting in Orlando, FL. Pr. Neil Korman, MD, PhD, FAAD spoke on March, 4th 2017 at the F076 – AUTOIMMUNE BLISTERING DISEASES: WHAT’S NEW scientific session, directed by Pr. […]

Keep Reading

EVENT February 24, 2017

IMNP Dermatology (Bullous Pemphigoid and Atopic Dermatitis) Educational Symposium

The following subjects in dermatology will be presented and discussed: The Need for New Therapies to Treat Bullous Pemphigoid and Atopic Dermatitis – Neil J. Korman, MD, PhD, Case Western, Cleveland, OH Rationale for Using Bertilimumab in a Bullous Pemphigoid Trial – Animesh A. Sinha, MD, PhD, University at Buffalo, NY Novel Pathogenic Developments in Atopic Dermatitis and Implications for […]

Keep Reading

EVENT February 22, 2017

IMNP Symposium at ACUTE LEUKEMIAS XVI, Munich, Feb 2017

Biology and Treatment Strategies Munich, Germany – February 19-22, 2017 Immune Pharmaceuticals Symposium Professor Kristoffer Hellstrand (University of Gothenburg) Presents the Role of Cytotoxic T-Cells in Remission Maintenance with Ceplene/Proleukin Therapy in AML      Professor Jacob Rowe (Shaare Zedek, Jeruslaem) Describes the Potential of Ceplene/Proleukin, the Only Clinically Proven Maintenance Therapy in AML

Keep Reading

EVENT January 27, 2017

Immune Pharmaceuticals Satellite Symposium at the International Symposium on Acute Leukemias XVI

Immune will hold a Satellite Symposium on February 20th, 2017 at the International Symposium on Acute Leukemias (ISAL) XVI in Munich, Germany. The satellite symposium is entitled: “Reinforcing the Efficacy of Immunotherapy for the maintenance of remission in AML with Ceplene” and will take place on Monday February 20th, 2017 from 12:45 – 13:45 CET in Lecture Hall III/IV in […]

Keep Reading

EVENT January 4, 2017

R&D Trends: What’s Changed in the Pharma Pipeline?

Panel discussion at the East/West CEO Conference, San Francisco, January 8th, 3:00-3:30 pm Susan Herbert, EVP, Global Head, Marketing & Strategy, EMD Serono; Tom Heyman, President, Johnson & Johnson Innovation, JJDC; Vivek Ramaswamy, CEO, Roivant Sciences and Axovant Sciences; Daniel Teper, CEO, Immune Pharmaceuticals Moderator: Joel Marcus, CEO, Alexandria Ventures Read more details about the conference here.

Keep Reading

EVENT June 3, 2016

CEO Dr. Daniel Teper to Present at the 2nd Annual Immuno-Oncology BD&L and Investment Forum

2nd Annual Immuno-Oncology BD&L and Investment Forum Hyatt Chicago Magnificent Mile June 3, 2016 CEO Dr. Daniel Teper to present at 12 PM The 2nd Annual Immuno-Oncology: BD&L and Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding & investment. We expect […]

Keep Reading

EVENT March 22, 2016

New Data on Ceplene® Cancer Immunotherapy to be Presented at the 2016 AACR Annual Meeting, 1:00-5:00 PM

Abstract # CT 116: Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia Presenters: Anna Martner, Ph.D. and  Kristoffer Hellstrand, M.D., Ph.D Poster session: Phase II, III, and Special Population Clinical Trials Session date and time: Tuesday Apr 19, 2016 1:00 PM – 5:00 PM Location: Convention Center, Halls G-J, […]

Keep Reading